U.S. Markets open in 8 hrs 44 mins

Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of Shares

President & CEO of Esperion Therapeutics Inc (30-Year Financial, Insider Trades) Timothy M Mayleben (insider trades) bought 7,500 shares of ESPR on 09/06/2019 at an average price of $34.55 a share. The total cost of this purchase was $259,125.

Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C. Esperion Therapeutics Inc has a market cap of $945.540 million; its shares were traded at around $34.80 with and P/S ratio of 6.76. Esperion Therapeutics Inc had annual average EBITDA growth of 10.80% over the past ten years. GuruFocus has detected 1 severe warning sign with Esperion Therapeutics Inc. .

CEO Recent Trades:

  • President & CEO Timothy M Mayleben bought 7,500 shares of ESPR stock on 09/06/2019 at the average price of $34.55. The price of the stock has increased by 0.72% since.

Directors and Officers Recent Trades:

  • 10% Owner Target N V Biotech bought 80,000 shares of ESPR stock on 09/04/2019 at the average price of $33.78. The price of the stock has increased by 3.02% since.

For the complete insider trading history of ESPR, click here

.This article first appeared on GuruFocus.